ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies

Clinical trial NCT04043845 · WITHDRAWN

Trial details

NCT number: NCT04043845
Sponsor: Dana-Farber Cancer Institute
Status: WITHDRAWN
Phase: Phase 1
Study type: INTERVENTIONAL

Chronic Lymphocytic Leukemia Waldenstrom Macroglobulinemia Mantle Cell Lymphoma Marginal Zone Lymphoma

Start date: 2020-02-03
Primary completion: 2020-02-03
Enrollment: 0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.